Innovations in Drug Discovery and Development

This Drug Discovery TechVision Opportunity Engine (TOE) depicts the current landscape and the new life sciences trends across drug discovery. This issue is focused on novel drug discovery platforms, including intelligent discovery and prodrug technologies for cancer immunotherapies and adjacent cell therapies. Several 'priority review' and 'orphan drug designation' cases are analyzed. The corresponding clinical trials scenario is also depicted.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.